FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis

Abha Sahni, Alok A. Khorana, Raymond B. Baggs, Hu Peng, Charles W. Francis

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

We have shown previously that fibrin(ogen) binds fibroblast growth factor 2 (FGF-2) and potentiates stimulation of endothelial-cell (EC) proliferation. We have now used 2 FGF-2 mutants differing only in the 5 residues constituting the binding site to characterize the importance of this interaction in angiogenesis. The nonbinding (2212) and binding (221*2) mutants stimulated EC proliferation by 2.2 ± 0.4-fold and 2.9 ± 0.3-fold over control, respectively, and both were similar to wild-type (wt) FGF-2 (2.5 ± 0.3-fold). Proliferationwasaugmentedbyfibrinogen to 5.3 ± 1.2-fold and 4.8 ± 0.8-fold with wtFGF-2 and 221*2, whereas no augmentation occurred with 2212 and fibrinogen. Using a placental explant model in a fibrin matrix, wtFGF-2 resulted in 2.6 ± 0.9-fold more growth over control, and 221*2 increased growth 3.3 plus or minus 0.9-fold. Vessel outgrowth with 2212 was minimal and comparable to control. Similarly, fibrinogen potentiated wtFGF-2 or 221*2-mediated angiogenesis in the chicken chorioallantoic membrane model. In a mouse Matrigel implant model, fibrinogen significantly increased angiogenesis with either wtFGF-2 or 221*2, whereas there was no augmentation with 2212. These results demonstrate that binding of FGF-2 to fibrin(ogen) mediated by the 5-residue FGF-2-fibrin(ogen) interactive site is required for augmented angiogenesis.

Original languageEnglish (US)
Pages (from-to)126-131
Number of pages6
JournalBlood
Volume107
Issue number1
DOIs
StatePublished - Jan 1 2006
Externally publishedYes

Fingerprint

Fibroblast Growth Factor 2
Fibrin
Fibrinogen
Endothelial cells
Cell proliferation
Endothelial Cells
Cell Proliferation
Chorioallantoic Membrane
Growth
Chickens
Binding Sites
estropipate
Membranes

ASJC Scopus subject areas

  • Hematology

Cite this

Sahni, A., Khorana, A. A., Baggs, R. B., Peng, H., & Francis, C. W. (2006). FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis. Blood, 107(1), 126-131. https://doi.org/10.1182/blood-2005-06-2460

FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis. / Sahni, Abha; Khorana, Alok A.; Baggs, Raymond B.; Peng, Hu; Francis, Charles W.

In: Blood, Vol. 107, No. 1, 01.01.2006, p. 126-131.

Research output: Contribution to journalArticle

Sahni, A, Khorana, AA, Baggs, RB, Peng, H & Francis, CW 2006, 'FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis', Blood, vol. 107, no. 1, pp. 126-131. https://doi.org/10.1182/blood-2005-06-2460
Sahni, Abha ; Khorana, Alok A. ; Baggs, Raymond B. ; Peng, Hu ; Francis, Charles W. / FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis. In: Blood. 2006 ; Vol. 107, No. 1. pp. 126-131.
@article{b5eb2da55351491bafbfe32530db5677,
title = "FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis",
abstract = "We have shown previously that fibrin(ogen) binds fibroblast growth factor 2 (FGF-2) and potentiates stimulation of endothelial-cell (EC) proliferation. We have now used 2 FGF-2 mutants differing only in the 5 residues constituting the binding site to characterize the importance of this interaction in angiogenesis. The nonbinding (2212) and binding (221*2) mutants stimulated EC proliferation by 2.2 ± 0.4-fold and 2.9 ± 0.3-fold over control, respectively, and both were similar to wild-type (wt) FGF-2 (2.5 ± 0.3-fold). Proliferationwasaugmentedbyfibrinogen to 5.3 ± 1.2-fold and 4.8 ± 0.8-fold with wtFGF-2 and 221*2, whereas no augmentation occurred with 2212 and fibrinogen. Using a placental explant model in a fibrin matrix, wtFGF-2 resulted in 2.6 ± 0.9-fold more growth over control, and 221*2 increased growth 3.3 plus or minus 0.9-fold. Vessel outgrowth with 2212 was minimal and comparable to control. Similarly, fibrinogen potentiated wtFGF-2 or 221*2-mediated angiogenesis in the chicken chorioallantoic membrane model. In a mouse Matrigel implant model, fibrinogen significantly increased angiogenesis with either wtFGF-2 or 221*2, whereas there was no augmentation with 2212. These results demonstrate that binding of FGF-2 to fibrin(ogen) mediated by the 5-residue FGF-2-fibrin(ogen) interactive site is required for augmented angiogenesis.",
author = "Abha Sahni and Khorana, {Alok A.} and Baggs, {Raymond B.} and Hu Peng and Francis, {Charles W.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1182/blood-2005-06-2460",
language = "English (US)",
volume = "107",
pages = "126--131",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis

AU - Sahni, Abha

AU - Khorana, Alok A.

AU - Baggs, Raymond B.

AU - Peng, Hu

AU - Francis, Charles W.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - We have shown previously that fibrin(ogen) binds fibroblast growth factor 2 (FGF-2) and potentiates stimulation of endothelial-cell (EC) proliferation. We have now used 2 FGF-2 mutants differing only in the 5 residues constituting the binding site to characterize the importance of this interaction in angiogenesis. The nonbinding (2212) and binding (221*2) mutants stimulated EC proliferation by 2.2 ± 0.4-fold and 2.9 ± 0.3-fold over control, respectively, and both were similar to wild-type (wt) FGF-2 (2.5 ± 0.3-fold). Proliferationwasaugmentedbyfibrinogen to 5.3 ± 1.2-fold and 4.8 ± 0.8-fold with wtFGF-2 and 221*2, whereas no augmentation occurred with 2212 and fibrinogen. Using a placental explant model in a fibrin matrix, wtFGF-2 resulted in 2.6 ± 0.9-fold more growth over control, and 221*2 increased growth 3.3 plus or minus 0.9-fold. Vessel outgrowth with 2212 was minimal and comparable to control. Similarly, fibrinogen potentiated wtFGF-2 or 221*2-mediated angiogenesis in the chicken chorioallantoic membrane model. In a mouse Matrigel implant model, fibrinogen significantly increased angiogenesis with either wtFGF-2 or 221*2, whereas there was no augmentation with 2212. These results demonstrate that binding of FGF-2 to fibrin(ogen) mediated by the 5-residue FGF-2-fibrin(ogen) interactive site is required for augmented angiogenesis.

AB - We have shown previously that fibrin(ogen) binds fibroblast growth factor 2 (FGF-2) and potentiates stimulation of endothelial-cell (EC) proliferation. We have now used 2 FGF-2 mutants differing only in the 5 residues constituting the binding site to characterize the importance of this interaction in angiogenesis. The nonbinding (2212) and binding (221*2) mutants stimulated EC proliferation by 2.2 ± 0.4-fold and 2.9 ± 0.3-fold over control, respectively, and both were similar to wild-type (wt) FGF-2 (2.5 ± 0.3-fold). Proliferationwasaugmentedbyfibrinogen to 5.3 ± 1.2-fold and 4.8 ± 0.8-fold with wtFGF-2 and 221*2, whereas no augmentation occurred with 2212 and fibrinogen. Using a placental explant model in a fibrin matrix, wtFGF-2 resulted in 2.6 ± 0.9-fold more growth over control, and 221*2 increased growth 3.3 plus or minus 0.9-fold. Vessel outgrowth with 2212 was minimal and comparable to control. Similarly, fibrinogen potentiated wtFGF-2 or 221*2-mediated angiogenesis in the chicken chorioallantoic membrane model. In a mouse Matrigel implant model, fibrinogen significantly increased angiogenesis with either wtFGF-2 or 221*2, whereas there was no augmentation with 2212. These results demonstrate that binding of FGF-2 to fibrin(ogen) mediated by the 5-residue FGF-2-fibrin(ogen) interactive site is required for augmented angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=30144444555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30144444555&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-06-2460

DO - 10.1182/blood-2005-06-2460

M3 - Article

C2 - 16160009

AN - SCOPUS:30144444555

VL - 107

SP - 126

EP - 131

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -